EQT VIII targets primarily control equity investments as well as significant influence investments in companies with strong market positions, significant potential for revenue and earnings growth, strong cash flows and a solid platform that can retain and attract high-quality management. EQT VIII will seek to make equity investments typically ranging between EUR 150 million and EUR 1,000 million. The geographical focus will primarily be Northern Europe and the fund will mainly focus on investments in the Healthcare, TMT and Services sectors.
Commitments by region
Commitments by type
Portfolio
Company | Sector | Country | Entry | Exit | SDG * |
---|---|---|---|---|---|
Facile | TMT | Italy |
Jun 2018 |
||
Banking Circle | TMT | Luxembourg |
Oct 2018 |
||
Cast & Crew | TMT, Services | United States |
Dec 2018 |
||
Azelis | Services | Luxembourg |
Nov 2018 |
||
Karo Pharma | Healthcare | Sweden |
Jan 2019 |
||
SUSE | TMT | Germany |
Mar 2019 |
||
Igenomix | Healthcare | Spain |
Jun 2019 |
||
Dellner Couplers | Industrial Technology | Sweden |
Jun 2019 |
||
Galderma | Healthcare | Switzerland |
Oct 2019 |
||
Aldevron | Healthcare | United States |
Oct 2019 |
||
Waystar | TMT | United States |
Oct 2019 |
||
Recover Nordic | Services | Norway |
Mar 2020 |
||
Schülke | Healthcare | Germany |
Jul 2020 |
||
SHL Medical | Healthcare | Switzerland |
Jan 2020 |
||
IFS | TMT | Sweden |
Sep 2020 |